SCHEDULE: Sphera Funds Discloses 5.51% Stake in ProMIS Neurosciences
Beneficial Ownership Report
Sphera Funds Management Ltd. and its affiliates have reported a 5.51% beneficial ownership stake in ProMIS Neurosciences Inc., totaling 3,122,090 common shares.
Summary
- Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP collectively reported beneficial ownership of 3,122,090 Common Shares of ProMIS Neurosciences Inc.
- This represents 5.51% of the total class of securities outstanding.
- The percentage is calculated based on 53,811,110 Common Shares outstanding as of September 26, 2025, and includes 2,826,903 warrants beneficially owned by the reporting persons, each exercisable into one Common Share.
- Ownership is held through Sphera Global Healthcare Master Fund (511,875 warrants, 0.90%) and Sphera Biotech Master Fund, L.P. (295,187 Common Shares and 2,315,028 warrants, 4.61%).
- The reporting persons disclaim beneficial ownership of the securities and the existence of a 'group' for Section 13(d) purposes.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant beneficial ownership stake by an institutional investor group. While not directly indicative of company performance, a substantial stake by a specialized healthcare fund can be interpreted as a positive signal of investor interest and confidence in ProMIS Neurosciences Inc.
Positives
- A significant institutional investor, Sphera Funds Management Ltd. and its affiliates, has disclosed a 5.51% beneficial ownership stake, potentially signaling confidence in ProMIS Neurosciences Inc.
Risks
- Reporting Persons disclaim beneficial ownership of the securities covered by this statement.
- Reporting Persons disclaim the existence of a 'group' for purposes of Section 13(d) of the Securities Exchange Act of 1934.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 09/26/2025 | Date as of which 53,811,110 Common Shares were outstanding, used for percentage calculation. |
| 09/30/2025 | Date of event which requires filing of this statement. |
| 10/03/2025 | Date ProMIS Neurosciences Inc. filed its Definitive Proxy Statement on Schedule 14A, providing the outstanding share count. |
| 10/23/2025 | Date of signing of the Schedule 13G filing. |
Recommendation
holdThis Schedule 13G filing primarily serves as a disclosure of beneficial ownership by an institutional investor group. While the 5.51% stake by Sphera Funds Management Ltd. and its affiliates indicates significant investor interest, the filing itself does not provide financial performance data, strategic updates, or operational insights necessary for a comprehensive investment recommendation. Investors should consider this ownership alongside the company's broader financial health, pipeline developments, and market conditions before making investment decisions. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis.
Keywords
ProMIS Neurosciences, Sphera Funds, beneficial ownership, Schedule 13G, common shares, warrants, institutional investment, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.